Introduction

This report provides an overview of current developments in integrated medical diagnostics, covering the emergence of new IV2D methods that combine IVD with current and developing imaging platforms. The drivers of this integration are reviewed including new disease biomarkers, single, combined and emerging imaging systems, as well as IT and patient-centred systems.

Features and benefits

• Assess the key technologies that will enable in vivo, in vitro diagnostic integration.
• Understand how IVD methods, biomarkers and imaging methods have been applied to challenges of diagnosis in breast cancer and Alzheimer’s disease.
• Discover how centres of expertise, such as academic departments, are driving new discoveries and offering valuable alliances to diagnostic companies.
• Understand the factors that are driving healthcare providers to develop improved healthcare programmes through integration in medical diagnostics.

Highlights

Today, diagnosis and treatment are increasingly integrated. This reflects developments in several key areas: scientific, diagnosis, evidence-based therapies, advancing personalized care and improved process efficiency. The need to improve patient diagnosis is today driving healthcare providers to improve management and process efficiency.

The rapidly evolving IV2D field offers important opportunities to diagnostic imaging companies. While imaging continues to see important refinements, the development of new imaging systems is challenging. In contrast, substantial numbers of in-vivo biomarkers are being discovered, offering combined “hybrid” integrations with imaging.

Siemens is a global provider of medical diagnostic systems, incorporating primary tests and instrumentation, IT platforms and software solutions, for clinical data handling and processing. Siemens is also developing technologies in the field of integrated diagnostics.

Your key questions answered

• What are the major imaging systems in diagnosis and how are they being applied to diagnosis in breast cancer and Alzheimer’s disease?
• What are the business models of some of the major diagnostic companies as they establish new integrated diagnostic and healthcare capabilities?
• What levels of support and capability do healthcare providers seek from companies offering products and services in the fields of diagnostics?
• What strategies are the major diagnostic companies taking to reduce costs of the healthcare products and services?
• Why is it anticipated that the next decade will see substantial growth in the integrated diagnostics field?